Johnson & Johnson reported a strong second-quarter performance, with pharmaceutical sales surpassing $15 billion for the first time. The medical devices segment also contributed significantly to the overall $23.7 billion sales, aided by 22.3% growth in cardiology. Despite a 43% decline in blockbuster Stelara sales due to biosimilar competition, J&J’s oncology portfolio, including Darzalex and newly launched medicines, drove robust growth. The company raised its 2025 operational sales and earnings guidance, reflecting confidence in sustained portfolio performance amid patent expirations and tariff challenges.